Upstream Bio, Inc. (UPB) Stock Forecast
UPB analyst forecast
as of October 18, 2026- Analyst consensus
- Buy 4.38 / 5 from 8 analysts
- Price target
- $31.14 average of analyst targets
- Upside to target
- +1,028.4% from the latest close
- Next earnings
- November 4, 2026 EPS estimate $-0.67
- 52-week range
- $2.76 – $32.60
UPB analyst ratings
8 analystsNumber of analysts at each rating.
UPB price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
UPB earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.73 | −$0.88 | −$0.52 | −$0.63 | −15.7% | 8 |
| Current fiscal year (2026) | −$2.90 | −$3.26 | −$2.17 | −$2.66 | −9.2% | 8 |
| Next fiscal year (2027) | −$2.80 | −$3.46 | −$1.77 | −$2.90 | +3.5% | 7 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
UPB revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $480,290 | $0 | $1.0M | −29.7% | 7 |
| Current fiscal year (2026) | $2.7M | $1.8M | $3.4M | −5.2% | 7 |
| Next fiscal year (2027) | $1.4M | $0 | $3.3M | −49.6% | 6 |
UPB EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
UPB revenue: reported and forecast
UPB EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.71 | −$0.70 | −$0.70 | −$0.73 | −$0.73 | +2.6% | 4 up · 3 down |
| Current fiscal year (2026) | −$2.90 | −$2.84 | −$2.84 | −$2.90 | −$2.90 | −0.0% | 5 up · 3 down |
| Next fiscal year (2027) | −$3.03 | −$2.89 | −$2.89 | −$2.93 | −$2.80 | −7.5% | 3 up · 3 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
UPB earnings surprises
Reported EPS vs the consensus estimate for the last 9 quarters; UPB beat in 4 of 9.
What analysts expect from UPB
8 analysts cover Upstream Bio; their consensus rating is buy (4.38 on a 1–5 scale, where 5 is a strong buy). The average price target is $31.14, 1,028.4% above the latest close of $2.76. Analysts expect earnings of −$2.90 per share for 2026, −9.2% from a year earlier. For 2027 the average estimate is −$2.80 per share on revenue of $1.4 million. Upstream Bio beat the EPS estimate in 4 of the last 9 quarters.
Related: UPB income statement, UPB key metrics, UPB chart. See the UPB stock overview for the latest quote and news.
UPB forecast FAQ
What is Upstream Bio's price target?
The average analyst price target for Upstream Bio is $31.14, 1,028.4% above the latest close of $2.76.
Is Upstream Bio a buy, hold or sell?
Of 8 analysts covering Upstream Bio, 5 rate it a strong buy, 1 a buy, 2 a hold, 0 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Upstream Bio's EPS forecast?
Analysts forecast −$2.90 per share for 2026 (range −$3.26 to −$2.17); for 2027 the estimate is −$2.80.
What is Upstream Bio's revenue forecast?
The average revenue estimate for 2026 is $2.7 million, growth of −5.2%; for 2027 it is $1.4 million.
When does Upstream Bio report earnings?
Upstream Bio is expected to report results for the quarter ending September 30, 2026 on November 4, 2026 before the market opens; the EPS estimate is $-0.67.
Does Upstream Bio usually beat earnings estimates?
Upstream Bio reported EPS at or above the analyst estimate in 4 of the last 9 quarters.